Blocking immunosuppressive neutrophils deters pY696-EZH2–driven brain metastases is a research paper published in Science Translational Medicine (2020). On theSindex it has a DataRank of 0. It has been cited 121 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: R01 CA112567
National Institutes of Health
Grant: R01 CA184836
National Institutes of Health
Grant: R01 CA208213
National Institutes of Health
Grant: R21 CA223102
National Institutes of Health
Grant: P30 CA016672
Cancer Prevention and Research Institute of Texas
Grant: RP180734
Australian National Health and Medical Research Council grant
Grant: APP1113867
NCI NIH HHS
Grant: R01 CA231149
National Institutes of Health
Grant: 1R21CA223102-01
Co-targeting PDAC tumor cells and the microenvironment to succeed in EGFR/ErbB2-targeted therapy
National Institutes of Health
Grant: 3P30CA016672-41S4
Cancer Center Support (CORE) Grant
National Institutes of Health
Grant: 5R01CA208213-04
Inhibition of brain metastasis by blocking MAPK12 driver kinase functions
National Institutes of Health
Grant: 5R01CA184836-02
Target p70S6K for Chemodietary Prevention/Early Intervention of ER- Breast Cancer
National Health and Medical Research Council (NHMRC)
Grant: 1113867
Translating molecular determinants of susceptibility and progression in breast cancer
National Institutes of Health
Grant: 5R01CA112567-09
Stromal activation in the progression of high ErbB2/1433zeta DCIS to IBC
FWCI
4.62
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer
Additional file 1 of Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer
Additional file 2 of Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer
Additional file 2 of Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer
Additional file 3 of Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer
Additional file 3 of Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer
Additional file 4 of Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer
Additional file 4 of Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer
Additional file 5 of Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer
Additional file 5 of Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer
Additional file 6 of Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer
Additional file 6 of Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer
Additional file 7 of Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer
Additional file 7 of Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer
Additional file 8 of Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer
Additional file 8 of Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer
Additional file 9 of Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer
Additional file 9 of Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer